No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Oppenheimer Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Raises Target Price to $12
Analysts' Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
Positive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership With AbbVie
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap